0107 Arsenal BMS
BioCentury & Getty Images

Deals

ArsenalBio reaches next stage of maturity with BMS deal

In first deal with major pharma, ArsenalBio putting synthetic biology toolkit to the test

In its first deal with a major pharma, ArsenalBio will use its synthetic biology toolkit to create programmable T cell therapies against solid tumor targets.

Jan 8, 2021 | 2:22 AM GMT

In its first deal with a major pharma, ArsenalBio will put its synthetic biology toolkit to the test in creating programmable T cell therapies against solid tumor targets chosen by BMS.

ArsenalBio as among the first companies to originate from the Parker Institute for Cancer Immunotherapy

Read the full 1040 word article

How to gain access

Continue reading with a
two-week free trial.